Mount Sinai researchers are developing a novel two-drug approach to treating diabetes that enables the regeneration of insulin-producing pancreatic beta cells. One of the drugs, harmine, has never been studied carefully in humans. The Mount Sinai team in 2021 received approval from the FDA to conduct a phase 1 trial of the drug.